In the general population, raised levels of inflammatory markers are stronger predictors of fatal than nonfatal cardiovascular disease (CVD) events. People with HIV have elevated levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), and D-dimer; HIV-induced activation of inflammatory and coagulation pathways may be...
-
2014 (v1)PublicationUploaded on: April 14, 2023
-
2008 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2002 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2014 (v1)Publication
No description
Uploaded on: May 13, 2023 -
2013 (v1)Publication
Rheumatoid arthritis (RA) is a chronic inflammatory immune-mediated systemic disease which primarily affects the joints. Leflunomide (LFN) is a disease modifying anti-rheumatic drugs (DMARDs) which acts by inhibiting the synthesis of pyrimidines. Several trials have demonstrated the efficacy and safety of LFN alone or in combination with...
Uploaded on: April 14, 2023 -
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2014 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2011 (v1)Publication
B-cells abnormalities leading to autoantibody production play a central role in Systemic Lupus Erythematosus (SLE) pathogenesis. B-cell targeted therapies, including anti-B lymphocyte stimulator (BLyS) and anti-CD20 monoclonal antibodies, are at forefront of new SLE treatments. Biologic agents targeting specific pathways (i.e. T-B lymphocyte...
Uploaded on: March 31, 2023 -
2009 (v1)Publication
The ongoing progresses in the knowledge of the pathogenic mechanisms of various inflammatory or immune-mediated diseases and the availability of innovative biotechnological approaches have lead to the development of new drugs which add to conventional treatments. TNF-alpha inhibitors (Infliximab, Adalimumab and Etanercept) have demonstrated...
Uploaded on: April 14, 2023 -
2011 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2011 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2005 (v1)Publication
This article reviews the role of emerging biologic drugs for the treatment of rheumatoid arthritis (RA). Besides anti-tumor necrosis factor (TNF)-alpha and anti-interleukin (IL)-1 agents (Infliximab, Adalimurnab, Etanercept and Anakinra) whose clinical efficacy is now established, new drugs have been proposed for the therapy of rheumatoid...
Uploaded on: December 2, 2022 -
2013 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
No description
Uploaded on: March 27, 2023